What Happened to Concerns About Human Enhancement?
By R. Jean Cadigan, Margaret Waltz, Rebecca Walker, Rami Major and Incidental Enhancements Research Group,
The Hastings Center: Bioethics Forum
| 04. 25. 2023
Prominent science policy reports that set the stage for the recent Third International Summit on Human Genome Editing all raise questions about human enhancement. Enhancement concerns also consistently loom large in public attitudes on possible uses of these genomic technologies. It may seem surprising, then, that enhancement received little formal attention at the Summit. Instead, the Summit focused elsewhere–on issues of access to emerging forms of somatic cell genome editing for genetic disease. Here we report our observations on the Summit’s de-emphasis of enhancement questions and suggest some consequences of continuing this trend in subsequent science policy deliberations.
Despite its absence from the Summit’s agenda, the topic of genome editing for human enhancement did spontaneously bubble up at the meeting in interesting ways. On the first day, outside the Summit’s venue, London’s Francis Crick Institute, protesters passed out pamphlets titled “Stop Designer Babies.” At first it seemed as if the protest would succeed in making enhancement an important topic at the Summit. In the opening session, Robin Lovell-Badge, chair of the Summit’s organizing committee, referenced the protesters and also noted...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...